Cargando…

Synthetic Lethal Screen Identifies NF-κB as a Target for Combination Therapy with Topotecan for patients with Neuroblastoma

BACKGROUND: Despite aggressive multimodal treatments the overall survival of patients with high-risk neuroblastoma remains poor. The aim of this study was to identify novel combination chemotherapy to improve survival rate in patients with high-risk neuroblastoma. METHODS: We took a synthetic lethal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsang, Patricia S, Cheuk, Adam T, Chen, Qing-Rong, Song, Young K, Badgett, Thomas C, Wei, Jun S, Khan, Javed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364855/ https://www.ncbi.nlm.nih.gov/pubmed/22436457 http://dx.doi.org/10.1186/1471-2407-12-101

Ejemplares similares

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma
por: Sottile, Francesco, et al.
Publicado: (2012)

Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
por: Borankova, Karolina, et al.
Publicado: (2023)

Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan
por: Chaturvedi, Nagendra K., et al.
Publicado: (2016)

Protocol for Comprehensive Synthetic Lethality Screens
por: Romero-Moya, Damia, et al.
Publicado: (2020)

An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with (177)Lu-DOTATATE for the treatment of neuroblastoma
por: Tesson, Mathias, et al.
Publicado: (2018)

Novel Synthetic Monoketone Transmute Radiation-Triggered NFκB-Dependent TNFα Cross-Signaling Feedback Maintained NFκB and Favors Neuroblastoma Regression
por: Aravindan, Sheeja, et al.
Publicado: (2013)

Approaches to Identifying Synthetic Lethal Interactions in Cancer
por: Thompson, Jordan M., et al.
Publicado: (2015)

Topotecan reduces sepsis‐induced acute lung injury and decreases the inflammatory response via the inhibition of the NF‐κB signaling pathway
por: Wang, Xiaoxia, et al.
Publicado: (2022)

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
por: Azorsa, David O, et al.
Publicado: (2009)

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
por: Taschner-Mandl, Sabine, et al.
Publicado: (2015)

Genetic landscape of T cells identifies synthetic lethality for T-ALL
por: O’Meara, Connor P., et al.
Publicado: (2021)

A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis
por: Kranz, Dominique, et al.
Publicado: (2014)

Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen
por: Glinkina, Kseniya, et al.
Publicado: (2022)

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
por: Castells-Roca, Laia, et al.
Publicado: (2021)

Reply to: Target expression is a relevant factor in synthetic lethal screens
por: Gilad, Yosi, et al.
Publicado: (2022)

Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma
por: Boboila, Shuobo, et al.
Publicado: (2018)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series
por: De Ioris, Maria Antonietta, et al.
Publicado: (2023)

A Synthetic Lethal Screen Identifies a Role for Lin-44/Wnt in C. elegans Embryogenesis
por: Hartin, Samantha N., et al.
Publicado: (2015)

Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast
por: Marhold, Maximilian, et al.
Publicado: (2018)

A synthetic lethal screen identifies HDAC4 as a potential target in MELK overexpressing cancers
por: Zhou, Lin, et al.
Publicado: (2021)

Rapid-SL identifies synthetic lethal sets with an arbitrary cardinality
por: Dehghan Manshadi, Mehdi, et al.
Publicado: (2022)

Target expression is a relevant factor in synthetic lethal screens
por: Schultz, Iman J., et al.
Publicado: (2022)

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma
por: Keller, Kaylee M., et al.
Publicado: (2022)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models()
por: Zhang, Libo, et al.
Publicado: (2017)

Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma
por: Wei, Jun S., et al.
Publicado: (2013)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment
por: Li, Jian, et al.
Publicado: (2016)

A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells
por: Beetham, Henry, et al.
Publicado: (2019)

Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma
por: Wittig-Blaich, Stephanie, et al.
Publicado: (2017)

Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer
por: Feng, Junru, et al.
Publicado: (2022)

Identifying collateral and synthetic lethal vulnerabilities within the DNA-damage response
por: Pinoli, Pietro, et al.
Publicado: (2021)

Methodological approaches in application of synthetic lethality screening towards anticancer therapy
por: Canaani, D
Publicado: (2009)

A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells
por: Gilad, Yosi, et al.
Publicado: (2021)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hl6bva53k31l44u8f3gn60tn2s